Literature DB >> 11684742

Can recovery from depression be achieved?

R C Shelton1, A J Tomarken.   

Abstract

Even though a variety of treatments are available for depression, many patients experience an incomplete response, resulting in chronic functional impairment. The authors present a therapeutic heuristic that derives, in part, from a body of research that suggests that symptoms of mood disorders can be separated into three distinct components: somatic anxiety, which is most prominent in anxiety disorders, such as panic; anhedonia or low positive affect, which is most specific to depression; and general distress, which is present with both anxiety and depressive disorders. General distress and somatic anxiety appear to be significantly modulated by serotonin, and serotonergic drugs may exert their effects most significantly on these symptoms. On the other hand, positive affect, the dimension of reward-oriented motivation and enjoyment, appears to be most dependent on dopamine and, indirectly, norepinephrine. Thus a theoretical heuristic can be derived on the basis of the predominance of residual symptoms. Serotonergic agents would be chosen for monotherapy or augmentation for symptoms of distress. Alternatively, catecholaminergic drugs would be the first choice for anhedonia and decreased motivation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684742     DOI: 10.1176/appi.ps.52.11.1469

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  25 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia.

Authors:  Michael T Treadway; Nicholas A Bossaller; Richard C Shelton; David H Zald
Journal:  J Abnorm Psychol       Date:  2012-07-09

Review 3.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 4.  Psychopharmacologic treatment of pediatric major depressive disorder.

Authors:  Khrista Boylan; Soledad Romero; Boris Birmaher
Journal:  Psychopharmacology (Berl)       Date:  2006-08-08       Impact factor: 4.530

5.  Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?

Authors:  Laura B Zahodne; Oscar Bernal-Pacheco; Dawn Bowers; Herbert Ward; Genko Oyama; Natlada Limotai; Frances Velez-Lago; Ramon L Rodriguez; Irene Malaty; Nikolaus R McFarland; Michael S Okun
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

6.  Reduced reward learning predicts outcome in major depressive disorder.

Authors:  Elske Vrieze; Diego A Pizzagalli; Koen Demyttenaere; Titia Hompes; Pascal Sienaert; Peter de Boer; Mark Schmidt; Stephan Claes
Journal:  Biol Psychiatry       Date:  2012-12-08       Impact factor: 13.382

7.  Oxidative stress and glutathione response in tissue cultures from persons with major depression.

Authors:  Sara A Gibson; Željka Korade; Richard C Shelton
Journal:  J Psychiatr Res       Date:  2012-07-28       Impact factor: 4.791

8.  YL-0919, a dual 5-HT1A partial agonist and SSRI, produces antidepressant- and anxiolytic-like effects in rats subjected to chronic unpredictable stress.

Authors:  Yu-Hua Ran; Xiao-Xu Hu; Yu-Lu Wang; Nan Zhao; Li-Ming Zhang; Hua-Xia Liu; Yun-Feng Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

9.  Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.

Authors:  Ciara McCabe; Zevic Mishor; Philip J Cowen; Catherine J Harmer
Journal:  Biol Psychiatry       Date:  2009-12-24       Impact factor: 13.382

10.  Worth the 'EEfRT'? The effort expenditure for rewards task as an objective measure of motivation and anhedonia.

Authors:  Michael T Treadway; Joshua W Buckholtz; Ashley N Schwartzman; Warren E Lambert; David H Zald
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.